Internal Medicine, Nephrology · Stanford, CA
NPI
1922141951
Since 2007
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
300 Pasteur Dr
Stanford, CA, 94305
Phone (650) 723-4000
Groups this clinician bills Medicare through
Medicare paid, 2024
$97K
787 services
Medicare patients, 2024
233
Average age 69
Drug cost, 2024
$165K
1,426 prescriptions
Company payments, 2025
$126K
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Richard A Lafayette was code 99232 (hospital e&m - subsequent), 132 times for 58 patients. In total Richard A Lafayette billed 787 services in 24 codes, and Medicare paid $97K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-04-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 132 | 58 | $70.67 | $9,329 |
| 90961 ESRD Related Services (not dialysis) | Office | 112 | 22 | $266.32 | $30K |
| 99214 Office E&M - Established | Facility | 100 | 63 | $80.13 | $8,013 |
| 90945 Peritoneal Dialysis | Facility | 76 | 19 | $78.92 | $5,998 |
| 99233 Hospital E&M - Subsequent | Facility | 73 | 44 | $106.38 | $7,766 |
| 99214 Office E&M - Established | Office | 62 | 45 | $111.75 | $6,929 |
| 90935 Hemodialysis | Facility | 60 | 36 | $63.43 | $3,806 |
| 99215 Office E&M - Established | Facility | 26 | 21 | $124.17 | $3,228 |
| 99222 Hospital E&M - Initial | Facility | 23 | 23 | $116.59 | $2,682 |
| 90962 ESRD Related Services (not dialysis) | Office | 16 | 13 | $188.33 | $3,013 |
| 99223 Hospital E&M - Initial | Facility | 12 | 12 | $155.13 | $1,862 |
By year: 2022 $134K for 1,098 services; 2023 $107K for 847 services; 2024 $97K for 787 services.
Medicare prescription drug claims, 2024
In 2024, the drug Richard A Lafayette prescribed most often to Medicare patients was Amlodipine Besylate, with 143 prescriptions and refills. In total Richard A Lafayette wrote 1,426 Medicare prescriptions that cost $165K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Amlodipine Besylate Generic | 143 | 297 | 32 | $735 |
| Atorvastatin Calcium Generic | 95 | 226 | 23 | $651 |
| Losartan Potassium Generic | 75 | 157 | 14 | $517 |
| Prednisone Generic | 47 | 71 | Under 11 | $455 |
| Carvedilol Generic | 44 | 66 | Under 11 | $403 |
| Lisinopril Generic | 42 | 112 | 12 | $179 |
| Tacrolimus Generic | 35 | 78 | Under 11 | $7,265 |
| Furosemide Generic | 32 | 67 | Under 11 | $155 |
| Metoprolol Tartrate Generic | 32 | 60 | Under 11 | $129 |
| Allopurinol Generic | 31 | 65 | Under 11 | $343 |
| Omeprazole Generic | 30 | 52 | Under 11 | $304 |
| Farxiga Dapagliflozin Propanediol | 29 | 53 | Under 11 | $28K |
| Mycophenolate Mofetil Generic | 29 | 72 | Under 11 | $3,829 |
| Eliquis Apixaban | 28 | 32 | Under 11 | $20K |
| Sevelamer Carbonate Generic | 27 | 39 | Under 11 | $4,673 |
Brand drugs: 155 claims; generic drugs: 1,271 claims; opioid claims: 37.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Richard A Lafayette $126K ($98K in general payments such as food, travel and fees and $28K for research) from 14 companies. The largest payer was Novartis Pharmaceuticals Corporation with $45K.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 22 | $45K |
| Otsuka Pharmaceutical Development & Commercialization, Inc. 4578.T | 20 | $22K |
| Alexion Pharmaceuticals, Inc. AZN | 17 | $20K |
| Vertex Pharmaceuticals Incorporated VRTX | 17 | $17K |
| Calliditas Therapeutics US Inc. | 5 | $9,095 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $6,080 |
| Amgen Inc. AMGN | 1 | $4,500 |
| Novartis Pharma AG NVS | 4 | $1,877 |
| Apellis Pharmaceuticals, Inc. APLS | 2 | $301 |
| Mallinckrodt Hospital Products Inc. | 1 | $87.88 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.